The EC has granted approval for a fixed-duration regimen of AstraZeneca's Calquence (acalabrutinib) plus venetoclax.

PFE's new drug launches and Seagen acquisition are driving revenue gains despite COVID declines and market headwinds.

AstraZeneca’s share price has fallen a lot from its September high, but this could mean a tremendous opportunity for me to ...

AstraZeneca has received another boost to its aspirations in oncology with the FDA approval of Calquence, a next generation treatment for mantle cell lymphoma (MCL). Calquence (acalabrutinib ...

AstraZeneca's Calquence has hit the mark in the phase 3 AMPLIFY trial in chronic lymphocytic leukaemia (CLL), a study that chief executive Pascal Soriot recently said could be a "blockbuster ...

Real-world data show no significant differences in overall survival between patients with or without cytogenetic risk factors ...

During a live event, Danielle M. Brander, MD, discussed use of zanubrutinib in high-risk chronic lymphocytic leukemia.